Rallybio Corp
RLYBNasdaq
$16.42
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↑ +374.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$93.4M
Enterprise Value
$46.6M
P/E
—
P/S
108.9
P/B
1.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$858,000.00
Net Income (TTM)
-$7.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-3744.4%
Net Margin
-911.1%
ROE
-15.6%
ROIC
-728.9%
Debt / Equity
—
Net Cash
$46.8M
Return 1Y
+351.4%
Company profile
Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
- CEO
- Martin W. MacKay
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Connecticut
- Website
- rallybio.com
Management & directors
- Lieber Jonathan IChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
RLYB Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$212,000.000.0%
Diluted EPS-$1.46↓ -13.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $636,000.00 | $858,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$25.3M | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$33.1M |
| Net income | -$26.4M | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| Diluted EPS | — | -$1.84 | -$2.09 | -$1.84 | -$10.61 | -$1.59 |
| Operating cash flow | -$22.0M | -$45.5M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Free cash flow | -$22.2M | -$45.9M | -$57.3M | -$60.3M | -$49.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -9511.9% | -3853.6% |
| Net margin | — | — | — | — | -9084.1% | -1046.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $299,000.00 | $299,000.00 | $38,000.00 | $212,000.00 | $212,000.00 | $212,000.00 | $222,000.00 | $212,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.0M | -$12.1M | -$11.6M | -$9.7M | -$10.1M | -$6.9M | -$6.4M | -$8.7M |
| Net income | -$16.2M | -$11.5M | -$11.0M | -$9.4M | -$9.7M | $16.0M | -$5.9M | -$8.3M |
| Diluted EPS | -$0.37 | -$0.26 | -$9.51 | -$1.69 | -$0.22 | $0.36 | -$0.04 | -$1.46 |
| Operating cash flow | -$10.4M | -$13.5M | -$9.9M | -$10.2M | -$8.4M | -$6.5M | -$4.7M | -$8.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -5697.3% | -4035.5% | -30547.4% | -4561.3% | -4743.9% | -3266.5% | -2888.3% | -4119.3% |
| Net margin | -5430.1% | -3834.8% | -29063.2% | -4452.4% | -4576.9% | 7554.7% | -2636.0% | -3904.7% |
Company news
Jun 1, 2026
- 49d agoRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?stocktwits.com
- 49d agoRallyBio tries again for reverse merger, this time with Avenzobiopharmadive.com
- 49d agoRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placementfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Boudreau Helen M | Option exercise | 3,562 | $2.38 | $8,477.56 | filing |
| 2026-05-19 | ADAR1 Capital Management, LLC | Buy | 10,000 | $13.98 | $139,822.00 | filing |
| 2026-05-19 | ADAR1 Capital Management, LLC | Buy | 200 | $13.80 | $2,760.00 | filing |
| 2026-05-18 | ADAR1 Capital Management, LLC | Buy | 6,009 | $13.98 | $83,981.18 | filing |
| 2026-05-15 | ADAR1 Capital Management, LLC | Buy | 200 | $13.95 | $2,790.00 | filing |
| 2026-05-15 | ADAR1 Capital Management, LLC | Buy | 100 | $13.80 | $1,380.00 | filing |
| 2026-05-13 | ADAR1 Capital Management, LLC | Buy | 75,178 | $14.00 | $1.1M | filing |
| 2026-05-13 | ADAR1 Capital Management, LLC | Buy | 4,081 | $13.80 | $56,314.94 | filing |
| 2026-05-12 | ADAR1 Capital Management, LLC | Buy | 800 | $13.83 | $11,063.04 | filing |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 25,000 | $14.00 | $350,000.00 | filing |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 19,900 | $14.00 | $278,600.00 | filing |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 5,100 | $14.00 | $71,391.84 | filing |
| 2026-05-05 | ADAR1 Capital Management, LLC | Buy | 35,101 | $14.00 | $491,259.56 | filing |
| 2026-05-04 | ADAR1 Capital Management, LLC | Buy | 116,904 | $13.97 | $1.6M | filing |
| 2026-05-04 | ADAR1 Capital Management, LLC | Buy | 3,900 | $13.90 | $54,201.42 | filing |
| 2026-02-23 | Lieber Jonathan I· Chief Financial Officer | Sale | 789 | $5.06 | $3,992.34 | filing |
| 2026-02-18 | Lieber Jonathan I· Chief Financial Officer | Award | 2,500 | $0.00 | $0.00 | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.